| Identification | Back Directory | [Name]
1358099-18-9 | [CAS]
1358099-18-9 | [Synonyms]
TRAF6-UBC13 INHIBITOR C25-140
1-(4-benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one
1-Propanone, 3-[3,5-dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]- | [Molecular Formula]
C26H31N7O | [MDL Number]
MFCD27163630 | [MOL File]
1358099-18-9.mol | [Molecular Weight]
457.57 |
| Chemical Properties | Back Directory | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:62.5(Max Conc. mg/mL);136.59(Max Conc. mM) | [form ]
Solid | [pka]
-0.22±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity[1]. | [in vivo]
C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model[1].
C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model[1].
C25-140 (10 mg/kg; i.v.) treatment shows that the Cmax, AUC, t1/2 and Vd are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively[1].
C25-140 (10 mg/kg; p.o.) treatment shows that the Cmax, AUC, t1/2 and Vd are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively[1].
C25-140 (10 mg/kg; i.p.) treatment shows that the Cmax, AUC, t1/2 and Vd are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively[1]. | Animal Model: | R 837-induced psoriasis mouse model (male BALB/c mice)[1] | | Dosage: | ~1.5 mg/kg | | Administration: | Topically to the shaved back and the right ear; twice daily for 6 days | | Result: | Showed a dose-dependent improvement of RA disease outcome. |
| Animal Model: | Collagen-induced arthritis (CIA) model in DBA1/J mice[1] | | Dosage: | 6 mg/kg, 10 mg/kg, 14 mg/kg | | Administration: | Given i.p.; twice daily for 14 days | | Result: | Ameliorated the arthritic index to almost baseline levels in this efficacy model at doses of 10 and 14 mg/kg. Dose-dependently improved symptoms of RA including inflammation and structural damage. |
| Animal Model: | BALB/C mice[1] | | Dosage: | 10 mg/kg | | Administration: | I.v. (Pharmacokinetic Analysis) | | Result: | The Cmax, AUC, t1/2 and Vd were 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively.
|
| [storage]
Store at -20°C | [References]
[1] Brenke JK, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293(34):13191-13203. DOI:10.1074/jbc.RA118.002649 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|